ADAGNGMHealthcare·Biotechnology#292 in industry

Adagene Inc.

+43.0% · 90d

$3.56

-0.13 (-3.52%)

After-Hours $3.56(+0.00)

News

No News Yet

Press releases and SEC filings for ADAG will appear here as they are published.

Check back later for updates

Key Data

Market Cap$235.2M

Open$3.67

Prev Close$3.69

Day Range$3.51 – $3.84

52W Range$1.30 – $4.75

Volume92,117

P/E (TTM)—

EPS$-0.38

Dividend Yield—

Beta0.59

Profit Margin-229.56%

Revenue Growth7332.80%

Price Target$9.40(+164.0%)

Analyst Ratings

Strong Buy6 analysts

Buy 5Hold 1Sell 0

About

Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer. The company also develops ADG116, a fully human anti-CTLA-4 antibody generated using NEObody technology, which is in phase 1b/2 clinical trials to treat advanced/metastatic solid tumors; ADG206, which is in phase 1 clinical development to treat advanced metastatic solid tumors; ADG104, anti-PD-L1 monoclonal antibody which is in phase 2 clinical development; and ADG125, a novel anti-CSF-1R mAb which is in Phase 2 clinical development. In addition, it is developing ADG138, a HER2xCD3 POWERbody which is in pre clinical trial to treat low expressing tumors, as well as resistant/refractory tumors; ADG152, a CD20xCD3 POWERbody which is in preclincal trial to treat off-tumor toxicities; ADG153, a masked anti-CD47 IgG1 SAFEbody, wihx is in preclinical trial for the treatment of hematologic and solid tumor; and CD28 T-cell engagers, an anti-CD28 bispecific POWERbody TCEs to treat solid tumors. Adagene Inc. was incorporated in 2011 and is headquartered in Suzhou, China.

Healthcare · Biotechnology

128 employees

www.adagene.com